This article has Open Peer Review reports available.
Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: efficacy in combination with hormonal therapy
© Fabi et al.; licensee BioMed Central Ltd. 2012
Received: 27 December 2011
Accepted: 22 September 2012
Published: 19 October 2012
Open Peer Review reports
Pre-publication versions of this article and author comments to reviewers are available by contacting email@example.com.
|27 Dec 2011||Submitted||Original manuscript|
|12 Jan 2012||Reviewed||Reviewer Report - Antonio Frassoldati|
|11 Mar 2012||Reviewed||Reviewer Report - Sara Hurvitz|
|11 Apr 2012||Author responded||Author comments - Alessandra Fabi|
|Resubmission - Version 2|
|11 Apr 2012||Submitted||Manuscript version 2|
|2 Jul 2012||Reviewed||Reviewer Report - Antonio Frassoldati|
|3 Jul 2012||Reviewed||Reviewer Report - Sara Hurvitz|
|6 Aug 2012||Author responded||Author comments - Alessandra Fabi|
|Resubmission - Version 3|
|6 Aug 2012||Submitted||Manuscript version 3|
|2 Sep 2012||Reviewed||Reviewer Report - Sara Hurvitz|
|Resubmission - Version 4|
|Submitted||Manuscript version 4|
|22 Sep 2012||Editorially accepted|
|19 Oct 2012||Article published||10.1186/1471-2407-12-482|
How does Open Peer Review work?
Open peer review is a system where authors know who the reviewers are, and the reviewers know who the authors are. If the manuscript is accepted, the named reviewer reports are published alongside the article. Pre-publication versions of the article and author comments to reviewers are available by contacting firstname.lastname@example.org. All previous versions of the manuscript and all author responses to the reviewers are also available.
You can find further information about the peer review system here.